MEK Inhibitors As a Chemotherapeutic Intervention in Multiple Myeloma

Overview

Journal Blood Cancer J

Date 2013 Mar 26

PMID 23524590

Citations 34

Authors

C Chang-Yew Leow

S Gerondakis

A Spencer

Affiliations

Soon will be listed here.

Abstract

The Ras/Raf/MEK/extracellular signal regulated kinase (ERK) (Ras/mitogen-activated protein kinases (MAPK)) signal transduction pathway is a crucial mediator of many fundamental biological processes, including cellular proliferation, survival, angiogenesis and migration. Aberrant signalling through the Ras/MAPK cascade is common in a wide array of malignancies, including multiple myeloma (MM), making it an appealing candidate for the development of novel targeted therapies. In this review, we explore our current understanding of the Ras/MAPK pathway and its role in MM. Additionally, we summarise the current status of small molecule inhibitors of MEK under clinical evaluation, and discuss future approaches required to optimise their use.

Citing Articles

Bayesian Graphical Regression.

Ni Y, Stingo F, Baladandayuthapani V J Am Stat Assoc. 2023; 114(525):184-197.

PMID: 36937091 PMC: 10021014. DOI: 10.1080/01621459.2017.1389739.

Bayesian graphical models for modern biological applications.

Ni Y, Baladandayuthapani V, Vannucci M, Stingo F Stat Methods Appt. 2022; 31(2):197-225.

PMID: 35673326 PMC: 9165295. DOI: 10.1007/s10260-021-00572-8.

SHP2 Inhibitors Show Anti-Myeloma Activity and Synergize With Bortezomib in the Treatment of Multiple Myeloma.

Zhou P, Xiao M, Li W, Sun X, Bai Y, Meng F Front Pharmacol. 2022; 13:841308.

PMID: 35462913 PMC: 9019471. DOI: 10.3389/fphar.2022.841308.

Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myeloma.

Adamia S, Bhatt S, Wen K, Chyra Z, Fell G, Tai Y Leukemia. 2022; 36(4):1088-1101.

PMID: 35082402 PMC: 8979823. DOI: 10.1038/s41375-021-01475-z.

Anti-tumor activity of the pan-RAF inhibitor TAK-580 in combination with KPT-330 (selinexor) in multiple myeloma.

Suzuki R, Kitamura Y, Ogiya D, Ogawa Y, Kawada H, Ando K Int J Hematol. 2021; 115(2):233-243.

PMID: 34741230 DOI: 10.1007/s12185-021-03244-1.

References

Domina A, Vrana J, Gregory M, Hann S, Craig R . MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol. Oncogene. 2004; 23(31):5301-15. DOI: 10.1038/sj.onc.1207692. View

Bommert K, Bargou R, Stuhmer T . Signalling and survival pathways in multiple myeloma. Eur J Cancer. 2006; 42(11):1574-80. DOI: 10.1016/j.ejca.2005.12.026. View

Patriotis C, Makris A, BEAR S, Tsichlis P . Tumor progression locus 2 (Tpl-2) encodes a protein kinase involved in the progression of rodent T-cell lymphomas and in T-cell activation. Proc Natl Acad Sci U S A. 1993; 90(6):2251-5. PMC: 46064. DOI: 10.1073/pnas.90.6.2251. View

ONeil B, Goff L, Kauh J, Strosberg J, Bekaii-Saab T, Lee R . Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2011; 29(17):2350-6. PMC: 3107750. DOI: 10.1200/JCO.2010.33.9432. View

Yu C, Wang S, Dent P, Grant S . Sequence-dependent potentiation of paclitaxel-mediated apoptosis in human leukemia cells by inhibitors of the mitogen-activated protein kinase kinase/mitogen-activated protein kinase pathway. Mol Pharmacol. 2001; 60(1):143-54. DOI: 10.1124/mol.60.1.143. View

Huang W, Yang A, Matsumoto D, Collette W, Marroquin L, Ko M . PD0325901, a mitogen-activated protein kinase kinase inhibitor, produces ocular toxicity in a rabbit animal model of retinal vein occlusion. J Ocul Pharmacol Ther. 2009; 25(6):519-30. DOI: 10.1089/jop.2009.0060. View

Iverson C, Larson G, Lai C, Yeh L, Dadson C, Weingarten P . RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer. Cancer Res. 2009; 69(17):6839-47. DOI: 10.1158/0008-5472.CAN-09-0679. View

Bonello L, Voena C, Ladetto M, Boccadoro M, Palestro G, Inghirami G . BRAF gene is not mutated in plasma cell leukemia and multiple myeloma. Leukemia. 2003; 17(11):2238-40. DOI: 10.1038/sj.leu.2403116. View

Solit D, Garraway L, Pratilas C, Sawai A, Getz G, Basso A . BRAF mutation predicts sensitivity to MEK inhibition. Nature. 2005; 439(7074):358-62. PMC: 3306236. DOI: 10.1038/nature04304. View

10.

Drysdale M, Brough P, Massey A, Jensen M, Schoepfer J . Targeting Hsp90 for the treatment of cancer. Curr Opin Drug Discov Devel. 2006; 9(4):483-95. View

11.

Ozaki K, Kosugi M, Baba N, Fujio K, Sakamoto T, Kimura S . Blockade of the ERK or PI3K-Akt signaling pathway enhances the cytotoxicity of histone deacetylase inhibitors in tumor cells resistant to gefitinib or imatinib. Biochem Biophys Res Commun. 2009; 391(4):1610-5. DOI: 10.1016/j.bbrc.2009.12.086. View

12.

Chng W, Gonzalez-Paz N, Price-Troska T, Jacobus S, Rajkumar S, Oken M . Clinical and biological significance of RAS mutations in multiple myeloma. Leukemia. 2008; 22(12):2280-4. PMC: 3864109. DOI: 10.1038/leu.2008.142. View

13.

Annunziata C, Hernandez L, Davis R, Zingone A, Lamy L, Lam L . A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression. Blood. 2010; 117(8):2396-404. PMC: 3062408. DOI: 10.1182/blood-2010-04-278788. View

14.

Gantke T, Sriskantharajah S, Sadowski M, Ley S . IκB kinase regulation of the TPL-2/ERK MAPK pathway. Immunol Rev. 2012; 246(1):168-82. DOI: 10.1111/j.1600-065X.2012.01104.x. View

15.

Chatterjee M, Stuhmer T, Herrmann P, Bommert K, Dorken B, Bargou R . Combined disruption of both the MEK/ERK and the IL-6R/STAT3 pathways is required to induce apoptosis of multiple myeloma cells in the presence of bone marrow stromal cells. Blood. 2004; 104(12):3712-21. DOI: 10.1182/blood-2004-04-1670. View

16.

Mitsiades N, Mitsiades C, Richardson P, McMullan C, Poulaki V, Fanourakis G . Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood. 2003; 101(10):4055-62. DOI: 10.1182/blood-2002-11-3514. View

17.

Ohren J, Chen H, Pavlovsky A, Whitehead C, Zhang E, Kuffa P . Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat Struct Mol Biol. 2004; 11(12):1192-7. DOI: 10.1038/nsmb859. View

18.

Huynh H, Chow P, Soo K . AZD6244 and doxorubicin induce growth suppression and apoptosis in mouse models of hepatocellular carcinoma. Mol Cancer Ther. 2007; 6(9):2468-76. DOI: 10.1158/1535-7163.MCT-07-0162. View

19.

Haass N, Sproesser K, Nguyen T, Contractor R, Medina C, Nathanson K . The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel. Clin Cancer Res. 2008; 14(1):230-9. DOI: 10.1158/1078-0432.CCR-07-1440. View

20.

Podar K, Chauhan D, Anderson K . Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia. 2008; 23(1):10-24. PMC: 3418600. DOI: 10.1038/leu.2008.259. View